Browsing Tag
AstraZeneca PLC
6 posts
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
Can fixed-duration oral therapy finally replace indefinite CLL treatment? AstraZeneca’s FDA win explains why
FDA approval of AstraZeneca’s CALQUENCE plus venetoclax introduces a fixed-duration oral option for frontline CLL. Find out why this matters for patients and investors.
Phase III evidence elevates BREZTRI in the competitive asthma landscape
Phase III data position AstraZeneca Plc’s BREZTRI for asthma growth. Discover the strategic, financial, and competitive implications.
AstraZeneca FY2025 results analysis: How oncology scale, China exposure, and pipeline depth are reshaping long-term earnings power
AstraZeneca’s FY2025 results reveal what’s driving growth, where risks are building, and how pipeline depth could shape earnings beyond 2030. Read the full analysis.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.